What is Excite Pharma Services?
Based in Lees Summit, Missouri, Excite Pharma Services operates as a comprehensive Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO). By providing end-to-end solutions that bridge the gap between laboratory research and commercial-scale production, the company serves as a critical partner for pharmaceutical entities. Their service portfolio is anchored by strict adherence to FDA, cGMP, and GLP standards, ensuring that clients maintain rigorous quality control throughout the drug lifecycle. As a specialized provider, Excite Pharma leverages its technical expertise to streamline chemistry services and manufacturing workflows, effectively reducing time-to-market for its diverse client base.
How much funding has Excite Pharma Services raised?
Excite Pharma Services has raised a total of $461K across 2 funding rounds:
Debt
$150K
Debt
$311K
Debt (2020): $150K with participation from PPP
Debt (2021): $311K led by PPP
Key Investors in Excite Pharma Services
PPP
Public-Private Partnership
What's next for Excite Pharma Services?
With the recent influx of capital, Excite Pharma Services is well-positioned to scale its infrastructure and expand its service capabilities to meet the rising demand for outsourced pharmaceutical development. The company is expected to prioritize the enhancement of its cGMP-compliant facilities, potentially increasing its throughput for complex chemical synthesis and manufacturing projects. By leveraging this late-stage financing, the firm aims to solidify its competitive advantage in the CRO/CDMO space, likely focusing on operational efficiency and the integration of advanced analytical technologies to support its growing roster of pharmaceutical partners. Future growth will likely be defined by the company's ability to maintain its high-compliance standards while scaling its capacity to handle larger, more intricate drug development programs.
See full Excite Pharma Services company page
